Cohort profile: Actionable Register of Geneva Outpatients and inpatients with SARS-CoV-2 (ARGOS).
COVID-19
epidemiology
public health
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
30 11 2021
30 11 2021
Historique:
entrez:
1
12
2021
pubmed:
2
12
2021
medline:
15
12
2021
Statut:
epublish
Résumé
The Actionable Register of Geneva Outpatients and inpatients with SARS-CoV-2 (ARGOS) is an ongoing prospective cohort created by the Geneva Directorate of Health. It consists of an operational database compiling all SARS-CoV-2 test results recorded in the Geneva area since late February 2020. This article aims at presenting this comprehensive cohort, in light of some of the varying public health measures in Geneva, Switzerland, since March 2020. As of 1 June 2021, the database included 360 525 patients, among which 65 475 had at least one positive test result for SARS-CoV-2. Among all positive patients, 37.6% were contacted only once, 10.6% had one follow-up call, 8.5% had two and 27.7% had three or more follow-up calls. Participation rate among positive patients is 94%. Data collection is ongoing. ARGOS data illustrates the magnitude of COVID-19 pandemic in Geneva, Switzerland, and details a variety of population factors and outcomes. The content of the cohort includes demographic data, comorbidities and risk factors for poor clinical outcome, self-reported COVID-19 symptoms, environmental and socioeconomic factors, prospective and retrospective contact tracing data, travel quarantine data and deaths. The registry has already been used in several publications focusing on symptoms and long COVID-19, infection fatality rate and re-infection. The data of this large real-world registry provides a valuable resource for various types of research, such as clinical research, epidemiological research or policy assessment as it illustrates the impact of public health policies and overall disease burden of COVID-19.
Identifiants
pubmed: 34848509
pii: bmjopen-2021-048946
doi: 10.1136/bmjopen-2021-048946
pmc: PMC8634627
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e048946Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
Clin Infect Dis. 2021 May 27;:
pubmed: 34043763
BMJ. 2020 Apr 17;369:m1470
pubmed: 32303495
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Lancet Infect Dis. 2021 Apr;21(4):e69-e70
pubmed: 32679085
BMJ. 2021 Mar 18;372:n628
pubmed: 33737413
BMJ. 2020 Mar 25;368:m1182
pubmed: 32213507
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Ann Intern Med. 2021 May;174(5):723-725
pubmed: 33284676
Clin Infect Dis. 2021 Sep 15;73(6):e1384-e1386
pubmed: 33949655
Infect Control Hosp Epidemiol. 2021 Oct 25;:1-3
pubmed: 34689854
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Lancet Infect Dis. 2020 Jun;20(6):678-688
pubmed: 32213332
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Infect Dis. 2020 Jul 28;71(15):889-890
pubmed: 32215618
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
N Engl J Med. 2020 May 28;382(22):e76
pubmed: 32302471
N Engl J Med. 2020 Aug 20;383(8):e56
pubmed: 32767891
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
BMJ. 2020 Jul 15;370:m2743
pubmed: 32669358
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264